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Abstract
Background: Seropositive rheumatoid arthritis (RA) is characterized by autoantibodies binding to citrullinated and
homocitrullinated proteins. We wanted to study the expression patterns of these disease-associated protein forms
and if the rheumatoid nodule and synovial tissue itself contain biologically active levels of citrullinating peptidyl
arginine deiminases 2, 3 and 4 and homocitrullination-facilitating neutrophil enzyme myeloperoxidase.
Method: Total of 195 synovial samples from metatarsal joints from five ACPA/RF-positive RA patients (n = 77),
synovial samples from knees of eight seropositive RA (n = 60), seven seronegative RA (n = 33) and five osteoarthritis
(n = 25) patients were analyzed for citrulline and homocitrulline contents using HPLC. The location of citrulline- and
homocitrulline-containing proteins, PAD 2, 3, 4 and myeloperoxidase were shown by immunostaining. Myeloperoxidase
and citrulline- or homocitrulline-containing proteins were stained on Western blot.
Results: Overall, necrosis was frequent in metatarsals of seropositive RA and absent in seronegative RA and
osteoarthritis patients. In histological analysis, there was a significant local patterning and variation in the citrulline
and homocitrulline content and it was highest in metatarsal synovial tissues of seropositive RA patients. We found
peptidyl arginine deiminase 2, 3 and 4 in the lining and sublining layers of intact synovial tissue. Myeloperoxidase
was found locally around necrotic areas. The tissues with necrosis contained the highest levels of citrulline and
homocitrulline.
Conclusions: Rheumatoid nodules and synovia contain significant amount of PAD2, 3 and 4 and myeloperoxidase
enzymes. These enzymes could explain the levels of citrulline and homocitrulline in seropositive RA synovial and
rheumatoid nodule tissues especially around necrotic tissue.
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease that is characterized by painful inflammation of
synovial joints. RA joint symptoms are characterized by
symmetric inflammation of joints and change in synovial
extracellular matrix, usually beginning in the metacarpal
or metatarsal joints. The local findings include a pannus
formation, i.e., invasive synovitis, formation of rheuma-
toid nodules and even pseudotumors of the synovial
membrane and influx of inflammatory cells. The patho-
logical process leading to RA is not fully understood.
Antibodies binding to citrullinated proteins (ACPA) are
a rheumatoid arthritis-specific finding that can precede
clinical disease onset by several years [1], which suggests
that these antibodies and their antigens could play a role
in the disease pathogenesis. In addition to the joint tis-
sues, citrullination in the lungs in response to smoking
has been suggested as an inducing event (reviewed in
[2]). Five different isoenzymes of citrullinating peptidy-
larginine deiminases (PADs) are found in humans. Of
these, PAD2 and PAD4 have been shown to be present
in RA synovial tissue [3]. PAD3 expression has been
connected to tissue damage in chick embryonic neural
stem cells [4]. However, so far the exact molecular
mechanism in pathogenesis and the anatomical origin of
these citrullinated and homocitrullinated proteins is not
known. To elucidate these processes we selected PADs
2, 3 and 4 and myeloperoxidase as target antigens for
the immunological stainings in this study.
The ACPA antigens identified so far are proteins oc-
curring naturally in the human body. In RA, citrullinated
fibrin, vimentin and histones are the focus of interest
and are considered possible autoantigens for citrulline-
binding antibodies [5]. Fibrin deposits are common in
inflamed synovium, histone citrullination is present in
extracellular trap structures created by neutrophils [6, 7]
and vimentin is citrullinated during apoptosis. It has also
been shown that in cell culture conditions citrullination
of fibronectin alters synovial fibroblast behavior and may
affect how these cells adhere to and invade the joint [8].
Since ACPA may develop years before disease onset, the
processes leading to antibody development are an ob-
vious subject of investigation. Recently, also antibodies
binding to carbamylated [9] and specifically to homoci-
trullinated sequences have been found in RA sera [10],
but also processes leading to formation of these anti-
bodies are unknown. It has been suggested that ACPA
and carbamylated protein-binding antibodies are distinct
systems [11] although overlapping of the presence of
both of these antibodies is frequent in RA [9, 10].
Citrulline and homocitrulline in proteins are products
of different posttranslational modifications (arginine
citrullination and lysine carbamylation respectively) but
have similar effects on protein structure and may create
epitopes that induce autoantibody responses. The forma-
tion of citrulline and homocitrulline contributes to protein
immunogenity [12, 13]. Antibodies binding to citrulline-
and homocitrulline-containing antigens contain partly
overlapping binding sites in RA sera [9, 10, 14] and in
animal models [13] suggesting some relationship between
these two modifications in RA.
Lately, the role of neutrophils in RA has raised interest
as neutrophil extracellular trap (NET) formation has
been suggested as a source of citrullinated antigens in
synovial fluid and pannus [7]. Myeloperoxidase, an
enzyme that is present in the granules of neutrophils,
has a function in host defense. Myeloperoxidase uses
negatively charged ions (for example iodine, chloride
and cyanate) [15, 16] to distort, for example, bacterial
proteins to inhibit their function. The addition of cyanate
to lysine side chain creates homocitrulline, which
makes NETs interesting also in respect of origin of
homocitrulline-binding antibodies.
We have already shown that citrulline and homoci-
trulline could be found simultaneously in the synovial
tissues of a single ACPA-positive RA patient [17]. In
this sequential study we show that the synovial tissues
of seropositive RA patients are characterized by nec-
rotic areas that contain high levels of citrulline and
homocitrulline and PAD and myeloperoxidase enzymes.
We also show the presence of myeloperoxidase in the
necrotic areas. Necrotic areas are more frequent in the
metatarsal than in the knee synovial tissues in seroposi-
tive RA patient tissues and absent in seronegative RA
and in osteoarthritis (OA) patient synovial tissues.
Methods
Subjects
Synovial tissues of feet were obtained from five RA pa-
tients [RA+ metatarsophalangeal (MTP) group, patients
20–25] with a severe destructive arthritis and deformity
of foot that were subjected to corrective orthopedic sur-
gery (four females and one male, age 64.8 ± 11.7 years).
All of these subjects fulfilled the diagnostic criteria of
the American College of Rheumatology for RA [18]. All
had a seropositive disease meaning that they had an ele-
vated level of rheumatoid factor (RF) and/or citrulline
peptide antibodies (ACPA). One patient had a biological
therapy with a tumor necrosis factor alpha (TNF-α)-
blocker, the others used conventional medication [disease-
modifying antirheumatic drugs (DMARDs)].
Synovial samples of knees were obtained from patients
that underwent a total knee replacement. We compared
the findings of four osteoarthritis (OA, patients 1–4)
with seven seronegative RA (RA-, patients 5–11) and
eight seropositive RA (RA+, patients 12–19) patients.
All RA patients fulfilled the diagnostic criteria of the
American College of Rheumatology for RA [18]. Duration
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of the disease with patients with RA was 21 years as mean.
RA patients with a seropositive disease were all females,
age 66.7 ± 7.15 years and the others with a seronegative
disease were six females and one male, age 70.0 ± 5.7
years. Patient number 6 had borderline RF level and
patient number 10 had juvenile RA. Eleven of all the
RA patients were using DMARDs and two patients
DMARDs + a TNF-α blocker and two patients (with a
seronegative disease) were not using any DMARDs
because of an improved disease course. Five patients
with osteoarthritis included three females and two
males, age 72.6 ± 1.9 years. C-reactive protein (CRP)
levels were similar in all patient groups, mean < 7 in
OA knee, RA+ knee and RA+ MTP, and 8.6 in RA-
knee. Seropositive RA patient number 17 had a CRP
level of 17 at the time of the operation and seronegative
RA patients 7, 9 and 10 had CRP levels at 13, 14 and 16
respectively.
Rheumatoid nodule tissues were collected beneath
MTP4 and MTP5 and from an olecranon bursa.
Anti-CCP
Antibodies binding to citrullinated proteins were mea-
sured by automated EliA-CCP (Phadia, Thermo Fisher
Scientific, Uppsala, Sweden).
Rheumatoid factor
Immunoglobulin (Ig)M-class rheumatoid factor levels
were measured from patient sera using an automated
analyzer Advia 1800 (Siemens Healthcare, Erlangen,
Germany).
Antibodies binding to citrulline- and homocitrulline-
containing type I and II collagen telopeptides
All available sera were tested by enzyme-linked im-
munosorbent assay (ELISA) as described before [10] for
binding of IgG to citrullinated and homocitrullinated
type I and II collagen carboxyterminal telopeptides
under standard conditions, and the binding was inhib-
ited by addition of soluble antigens to a final concen-
tration of 100 μg/ml. The two biotinylated peptides
corresponding to the carboxyterminal telopeptide of the
α1 chain of human type I collagen (NeoMPS, Stras-
bourg, France) represent amino acids 1193–1218, and
the two biotinylated peptides corresponding to the α1
chain of human type II collagen represent amino acids
1217–1241, counted from the amino terminus in the pro
α1 chains of type I or type II procollagen, respectively.
The synthetic peptides that were used as inhibitors in
the ELISA represent carboxyteminal ends of these par-
ent peptides. The peptide sequences have been described
before [10]. In each serum, the difference between bind-
ing with and binding without inhibition was calculated
for all peptide pairs.
Detection of protein-bound citrulline and homocitrulline
on high-performance liquid chromatography (HPLC)
Five approximately 10-mg (wet weight) samples were
cut from each tissue. Seventy-seven tissue specimens
were analyzed from seropositive RA metatarsal tissues,
60 from seropositive RA knees, 33 from seronegative RA
knees and 20 from OA knees. The samples were sub-
jected to extensive dialysis at 4 °C, 16 h against 0.2 M
NH4HCO3, pH 7.4 to separate free amino acids from
protein-bound ones and freeze-dried, then rehydrated in
dH2O, freeze-dried and hydrolyzed in 6 M HCl at 110 °C
for 16 h and freeze-dried. The samples were chemically
modified and analyzed on HPLC as reported previously
[13]. The levels of citrulline and homocitrulline in the sam-
ples were calculated from manually integrated peak area
using a calibration series of citrulline and homocitrulline.
Statistical analysis
The peak areas of citrulline and homocitrulline content
between tissues (n = 195 divided in four groups) were
assessed by Kruskal-Wallis test using Analyse-It version
2.26 for Excel 12+. The differences were considered
significant at p < 0.05.
Western blot
Treatment of samples: tissue samples from the rheuma-
toid nodules were divided into capsule and necrotic
inner mass, homogenized in phosphate-buffered saline
(PBS) containing Pierce protease inhibitor cocktail
(88666, Thermo Fisher Scientific). The samples were
fractionated by centrifugation to soluble and precipitate
fractions. Protein concentrations were determined by
the Bradford method. Both fractions were subjected to
collagenase I digestion (5273 CLSPA, Worthington
Biochemical, Lakewood, NJ, USA, 1:50 to protein con-
centration of digested sample in 0.2 M NH4HCO3 pH
7.4 overnight at +37 °C with agitation) and parallel sam-
ples to DNase I digestion (DNaseI, DN25, Sigma-Aldrich,
St. Louis, MO, USA, in 50 mM Tris-HCl, 10 mM
MgCl2 pH 7.5 for 75 minutes at +37 °C with agitation).
For demonstration of citrulline- and homocitrulline-
containing proteins, 50 μg of each sample and 5 μg of
carbamylated albumin were run on 10 % Bis-Tris SDS-
PAGE and blotted on nitrocellulose. The samples were
chemically modified with 2,3-butanedione and antipy-
rine in acidic conditions [13] and modified citrulline
and homocitrulline were detected with chemical adduct
recognizing rabbit polyclonal antibody KS350 and
horseradish peroxidase (HRP)-labelled anti-rabbit IgG
secondary antibody. The staining was visualized on
ECL film by chemiluminesence. For myeloperoxidase
staining, lysate from peripheral blood neutrophils was
used as a positive control and lysate from peripheral
blood mononuclear fraction was used as a negative
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control. Blot was stained with myeloperoxidase anti-
body (A0398, Dako, Glostrup, Denmark) and detected
with Alexa-Fluor 680 anti-rabbit IgG (A21109, Molecu-
lar Probes, Eugene, OR, USA) and visualized with an
Odyssey IR imager and Image Studio™ Software (LI-COR
Biosciences, Bad Homburg, Germany).
Immunohistochemistry
After collection the tissue pieces were kept -70 °C, fixed in
formalin and embedded in paraffin, 3.5-μm sections were
mounted on glass slides and stained with hematoxylin and
eosin (H&E). For immunostaining endogenous peroxi-
dases were blocked with Dako REAL Peroxidase-Blocking
Solution (S2023, Dako). Citrulline and homocitrulline
were stained using anti-peptidyl-citrulline, clone F95
mouse monoclonal antibody 1:250 (MABN328, EMD
Millipore Corp, Billerica, MA, USA) and PAD4 with
anti-human PAD4 antibody 1:300 (ab59965, Abcam,
Cambridge, MA, USA), after heat-induced antigen re-
trieval in citrate buffer pH 6. PAD2 enzyme was stained
with anti-human PAD2 antibody 1:250 (ab16478, Abcam)
and PAD3 with 1:50 (ab183209, Abcam) after heat-
mediated antigen retrieval in Tris-EDTA, pH 9 and
myeloperoxidase without antigen retrieval with anti-
human myeloperoxidase antibody 1:5000 (A0398,
Dako). The immunostainings were detected using Dako
REAL EnVision Detection system, Peroxidase/DAB+,
Rabbit/Mouse (K5007, Dako) and counterstained with
Mayer hematoxylin.
Double stainings of PAD3/KP1 and PAD3/F95 were
conducted after HIER in pH 9 Tris-EDTA, PAD3 1:25,
KP1 1:1000 and F95 1:25 overnight at +4 °C. PAD4/KP1
and PAD4/F95 were conducted after HIER in pH 6
citrate PAD4 1:50, KP1 1:1000 and F95 1:50 overnight
at +4 °C. KP1 was detected with Alexa Fluor 488 anti-
mouse IgG (A11029, Molecular Probes), F95 with Alexa
Fluor 488 anti-mouse IgM μ chain (A21042, Molecular
Probes) and PAD3 and PAD4 with Alexa Fluor 680 anti-
rabbit IgG (A21109, Molecular Probes). Nuclei were
stained with 1:500 Hoechst in PBS for 5 minutes.
Results
Citrulline and homocitrulline analyses
In the HPLC analyses, citrulline and homocitrulline
could be found in all studied tissues (Figs. 1 and 2). The
highest citrulline and homocitrulline levels were found
in the seropositive RA patients’ metatarsal synovial tis-
sues/rheumatoid nodules from this area (mean Cit 0.039
μg/mg wet weight tissue, mean Hcit 0.013 μg/mg wet
weight tissue), followed by seropositive RA patients’
knee synovial tissues (mean Cit 0.019 μg/mg, mean Hcit
0.004 μg/mg). The levels of citrulline and homocitrulline
in seronegative RA (mean Cit 0.007 μg/mg, mean Hcit
0.003 μg/mg) and in OA (mean Cit 0.007 μg/mg, mean
Hcit 0.002 μg/mg) patients’ synovial tissues were com-
parable with one another and significantly lower than in
seropositive RA tissues. There is about a tenfold diffe-
rence in the mass amount of citrulline compared to
homocitrulline, citrulline being more abundant. Overall
level of carbamylation is higher than the level of homo-
citrulline, since homocitrulline is just one of the prod-
ucts of carbamylation. Homocitrulline is also only one of
the products modifying protein structure as a result of
myeloperoxidase activity. When several pieces from the
same synovial tissue were analyzed, levels of citrulline
and homocitrulline varied significantly in different areas
of the same tissue. Interesting patterns between citrul-
line and homocitrulline were found in some of the RA
patient samples. When a sample contained a high level
of citrulline the level of homocitrulline was low and vice
versa (Fig. 2d). This phenomenon could not be detected
in other than seropositive RA tissue samples.
In the Kruskall-Wallis test the differences in citrulline
content between groups were significant between seroposi-
tive RA knee and seronegative RA knee tissues (p = 0.005),
seropositive RA knee and OA knee tissues (p = 0.002),
seronegative RA knee and seropositive RA metatarsal
tissues (p < 0.001) and OA knee and seropositive RA
metatarsal tissues (p < 0.001). The difference between
seropositive RA knee and seropositive RA metatarsal
tissues (p = 0.323) was not significant and there was no
difference between the citrulline content of seronega-
tive RA knee and OA knee tissues (p = 1.000). When
homocitrulline content were compared we found sig-
nificant differences between seropositive RA metatarsal
tissues compared to all knee tissue groups (p < 0.001 in
all comparisons), but the knee tissues did not differ
from each other in homocitrulline content (p = 1.000 in
all comparisons). The difference in homocitrulline con-
tent was in line with the difference in the presence of
necrotic areas in the tissue sections. Citrulline and
homocitrulline content of the tissue combined with in-
flammatory infiltrate and presence of necrosis in the
tissue showed cumulative effect (Fig. 3).
Significant levels of specific antibodies binding to cit-
rulline- and homocitrulline-containing type I and II col-
lagen telopeptides were found only in ACPA-positive RA
patients (Fig. 4). Both citrulline- and homocitrulline-
binding antibodies were elevated in the same patients.
Western blot
In the western blot analyses (Fig. 5) citrulline- or
homocitrulline-containing proteins were found mostly in
the precipitate fraction of the necrotic inner mass of the
rheumatoid nodule. When the sample was subjected to
collagenase I digestion, some of the citrulline- or
homocitrulline-containing large protein aggregates were
dissolved and the citrulline and homocitrulline (KS350)
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staining moved more to the lower molecular weight
proteins. DNase I digestion released most of the high
molecular weight aggregates suggesting the presence of
DNA-bound citrullinated or homocitrulline-containing
proteins in the necrotic inner mass of the rheumatoid
nodule. The strongest myeloperoxidase staining was also
detected in the precipitate fraction of the necrotic inner









Fig. 1 Citrulline and homocitrulline contents of synovial tissues. We compared the findings of four osteoarthritis (OA, patients 1–4) eight
seropositive RA (RA+) with seven seronegative RA (RA-, patients 5–11) and eight seropositive RA (RA+, patients 12–19) patients. Statistically
significant differences are indicated (**p < 0.01, ***p < 0.001). Patient RA serology is indicated as CCP/RF under the patient indicator. Panels A
and E represent HPLC analysis results for OA, B and F seronegative RA, C and G seropositive RA knee synovial tissues. Panels D and H
summarize the HPLC analysis data, including analyses of metatarsal tissue shown in detail in Fig. 2. Panels A to D represent citrulline and
panels E to H homocitrulline contents shown as μg/mg of wet weight tissue. The boxplot shows the median and interquartile range (IQR)
and the whiskers 95 % confidence interval (95 % CI), mean is shown as the blue line beside the boxplot. Individual measurements are shown
as circles. MTP metatarsophalangeal, OA osteoarthritis, RA rheumatoid arthritis
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Histology
In the basic H&E staining, both RA and OA synovial tis-
sues consisted of dense, mostly mature connective tissue
and infiltrated inflammatory cells. More adipose tissue
was found in the OA synovial samples, and the synovial
lining layer was thicker in the RA samples. One of the
seropositive RA knee synovial tissues was mostly necrosis
(patient 19), and in the metatarsal joint synovial tissues of
seropositive RA patient’s necrosis could be found in three
out of five samples (Fig. 3).
The localization of citrulline- and homocitrulline-
containing proteins, PAD2, PAD3, PAD4 and myeloper-
oxidase enzymes was defined by immunostaining (Figs. 6,
7, 8, 9 and 10). F95 antibody recognizing both citrulline
and homocitrulline [19] stained strongly the fibrinoid
extracellular matrix of necrotic RA synovial tissue
(Fig. 8b) and the synovial lining layer and the endothe-
lium of the small blood vessels in intact RA synovial tis-
sue. The cell-free necrotic tissue areas were completely
stained with the F95 antibody (Figs. 8b and 9b) showing
citrulline- or homocitrulline-containing proteins in these
areas. In intact tissue, F95 staining localized to cells with
macrophage-like appearance (large, rounded nucleus
and abundant cytoplasm), some fibroblast-like stromal
cells, extracellular matrix and endothelium of blood ves-
sels (Figs. 6b, 7b and 10a). PAD2 staining in the synovial
lining cells was localized in the vicinity of the nuclear
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Fig. 2 Citrulline and homocitrulline content of seropositive RA metatarsal synovial tissues. Seropositive RA metatarsal synovial tissues contained
the highest levels of citrulline and homocitrulline. a The samples were collected from locations shown in AP foot X-rays and each tissue specimen
was analyzed in five parallel analyses for (b) citrulline and (c) homocitrulline contents shown as μg/mg of wet weight tissue. The boxplot shows
the median and interquartile range (IQR) and the whiskers 95 % confidence interval (95 % CI), mean is shown as the blue line beside the boxplot.
Individual measurements are shown as circles. d Patient 24 sample 2, citrulline and homocitrulline contents represented for each individual
analysis. CCP cyclic citrullinated peptide, RF rheumatoid factor
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(Figs. 5c, 7c, 9c and 10b). In the necrotic tissue PAD2 was
sporadic, possibly localizing in areas with cell remnants
co-localizing with disperse myeloperoxidase staining
(Fig. 8c). PAD3 staining in both RA and OA tissue was
both nuclear and cytoplasmic in the cells of the synovial
lining layer and endothelium of blood vessels (Figs. 6d, 7d,
10c). In necrotic areas of RA tissue, PAD3 was staining
diffusely to the extracellular matrix and in the nucleus and
cytoplasm of the few intact cells (Figs. 8d and 9d). In RA
tissue (Fig. 10f), but not in OA (Fig. 10e), cytoplasmic
PAD4 expression was detected in macrophage-like syno-
viocytes both in the synovial lining and sublining layers
and endothelium of blood vessels, also few positive cells
were seen in deeper layers (Figs. 6e, 7e and 9e). In necrotic
areas, PAD4 stained diffusely to the matrix (Figs. 8e
and 9e). In the intact tissue adjacent to necrosis, PAD3
and PAD4 staining co-localized to the cells positive for
macrophage marker KP1 (Figs. 11 and 12). In seropositive
RA, tissue myeloperoxidase staining was localized in the
extracellular matrix of the synovial lining layer and some
intact small cells (neutrophils) and in local dispersed areas
(disrupted neutrophils) (Fig. 7f). In necrotic tissue, diffuse
myeloperoxidase was found in the matrix, but not in
intact cells, suggesting release of myeloperoxidase from
neutrophils (Fig. 8f). Also intact neutrophils were found
in the intact tissue adjacent to necrosis and in the synovial
lining layer (Figs. 9f and 10d). No myeloperoxidase
staining was found in OA tissue (Fig. 6f ).
Discussion
Since ACPA and carbamylated protein antibodies are a
sign of disease severity and a predictor of joint damage
in RA, we wanted to study the expression patterns cit-
rulline- and homocitrulline-containing proteins in tissue
from RA and control patients. We had the opportunity
of collecting and comparing RA synovial tissues from
metatarsal and knee joints and found interesting differ-
ences between these two anatomical locations both in
histology and citrulline and homocitrulline formation.
Expression of citrullinating peptidyl arginine deiminases
2, 3 and 4 and homocitrullination-facilitating neutrophil
enzyme myeloperoxidase were studied, because these en-
zymes contribute to formation of these altered proteins.
The staining of PAD2, PAD3 and PAD4 enzymes local-
ized to the lining in OA and both the lining and sublining
layers of synovial tissue in RA. PAD2 was found in the
synovial lining and sublining layers and endothelium of
blood vessels. PAD4 was found in the lining and sublining
layers of intact RA synovial tissue and diffusely in the
necrotic tissue, but not in OA tissue. The diffuse PAD4
staining in the necrotic tissue could be due to release
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Fig. 3 Citrulline and homocitrulline content averages combined
with necrosis and inflammatory score. Inflammatory cell infiltration
and necrosis were scored from 0 to 3 by tissue area. Asterisk indicates
that no histology data is available for patients 6 and 7. Citrulline and
homocitrulline contents were measured from parallel samples to
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Fig. 4 Inhibition-ELISA analysis of serum antibodies binding to citrulline- and homocitrulline-containing type I and type II collagen telopeptides.
Results are shown as percentage of inhibition in standard conditions. Mean +2 SD for 72 healthy control sera is indicated by the dotted line.
MTP metatarsophalangeal, OA osteoarthritis, RA rheumatoid arthritis



















1 Protein std 
2 Necrotic inner mass, soluble fraction
3 Collagenase I digestion of sample 2
4 Dnase I digestion of sample 2
5 Necrotic inner mass of rheumatoid
nodule, precipitate fraction
6 Collagenase I digestion of sample 5
7 Dnase I digestion of sample 5
8 Capsule of rheumatoid nodule, 
precipitate fraction
9 Collagenase I digestion of sample 8
10 Dnase I digestion of sample 8
11 Carbamylated (KCNO-treated) human
albumin
g Granulocyte lysate
m Mononuclear cell lysate
Fig. 5 Western blot analysis of citrulline- and homocitrulline-containing proteins and myeloperoxidase in rheumatoid nodule protein samples (a) Ponceau
S protein staining of rheumatoid nodule protein samples, (b) modified citrulline and homocitrulline staining of same samples, (c) myeloperoxidase staining.
Tissue samples from rheumatoid nodule were divided into capsule and necrotic inner mass. The samples were fractionated by centrifugation to soluble









Fig. 6 OA synovial tissue histology. a H&E, (b) citrulline and homocitrulline (F95), (c) PAD2, (d) PAD3, (e) PAD4 and (f) MPO staining. The scale bar
indicates 50 μm. L lumen of synovial cavity, blue arrow synovial lining layer, double-headed arrow synovial stroma
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of PAD4 from disrupted neutrophils discussed in detail
below, or alternatively unspecific binding of the antibody.
Our results are in concordance with previous findings,
where PAD2 and PAD4 were shown to be present in RA
synovial tissue [3] and plastic adherent macrophage-like
cells isolated from peripheral blood monocyte fraction
[20]. PAD3 expression in the synovial tissue has not been
shown previously but PAD3 mRNA was found recently
in synovial tissue, not in cultured synovial cells [21]. In
our specimens, PAD3 staining was strongest in the
macrophage-like synoviocytes in the lining layer of OA
and lining and sublining layers in RA synovial tissue
(Figs. 6 and 7) co-localizing with macrophage marker KP1
(Fig. 11). This could explain the earlier PAD3 mRNA
finding [21], since inflammatory macrophages are not
long-lived in cell culture. Peripheral blood monocytes
and macrophage-like adherent cells isolated from per-
ipheral blood monocyte fraction did not seem to ex-
press PAD3 in an earlier study [20]. This could indicate
that in addition to differentiation to macrophages also
inflammatory activation is needed for PAD3 expression.
In our study, some PAD3 staining was also detected in
synovial stromal cells with more fibroblast-like morph-
ology (Figs. 7d and 9d). The exact role of PAD3 in RA
context remains to be clarified, but interestingly, PAD3
involvement in calcium-induced cell death pathway in
neural stem cells was shown recently [4]. This earlier
study suggested a role for PAD3 as a regulator of cell
death or survival in neural stem cells. A similar role in
regulation of synovial growth could be an interesting
phenomenon from the perspective of RA disease
progression also. To verify this hypothesis, the role and
effect of PAD3 expression and activation in inflamed
tissue needs further studies on functional level.
Citrulline- and homocitrulline-containing proteins lo-
calized to the necrotic areas of rheumatoid nodule and
synovial tissue, as shown here by F95 staining and earlier
by staining with anti-modified citrulline antibodies [22].
It is notable, that these antibodies, do not make a
distinction between these two structurally homological
amino acids [19] and thus some of the earlier findings
concerning citrulline may involve homocitrulline as well
when immunological detection methods have been used.











Fig. 7 RA synovial tissue histology. a H&E, (b) citrulline and homocitrulline (F95), (c) PAD2, (d) PAD3, (e) PAD4 and (f) MPO staining. The scale bar
indicates 50 μm. L lumen of synovial cavity, blue arrow synovial lining layer, double-headed arrow synovial stroma, black arrow intact neutrophil,
arrowhead disrupted neutrophil
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in hydrolyzed tissue samples. Some necrotic areas could
be found in seropositive RA knee synovial tissues. Fi-
brinoid necrosis was absent in the seronegative RA and
OA knee synovial tissues, where only low levels of citrul-
line and homocitrulline was found. The highest content
of both were found in the seropositive RA metatarsal syn-
ovial tissues that were characterized by fibrinoid necrosis
(Figs. 1 and 2). In our data, the immunostaining results
were consistent with the HPLC analysis showing staining
by F95 antibody as well as PAD2, PAD3, PAD4 and mye-
loperoxidase (Figs. 8 and 9). The reliability of immuno-
staining of necrotic tissue is always a challenge and any
conclusions should be considered critically. Therefore
we prepared homogenates of necrotic tissue showing
the binding of chemically modified citrulline- and
homocitrulline-binding antibodies (KS350) to high mo-
lecular weight citrullinated or homocitrullinated pro-
teins in this tissue. Digestion of DNA from the sample
released some of the citrulline- or homocitrulline-
containing proteins. Finding myeloperoxidase by Western
blotting (Fig. 4), and in the histological sections of the
necrotic area (Figs. 8 and 9), suggests that indeed
neutrophils are involved in the seropositive RA chronic
inflammation.
Myeloperoxidase is an enzyme found in granules of
intact neutrophils. When an object is too big to be
ingested, neutrophils use their chromatin and the
enzymes from their granules as the last available defense
mechanism of forming extracellular traps (NETs) [23]
and these have been suggested as sources of citrullinated
autoantigens [7]. Histone citrullination by PAD-enzyme
releases the chromatin packing [24]. RA neutrophils are
prone to form NETs. NET components have been found
in RA blood [25] and synovial fluid and active PAD
enzymes [26] in synovial fluid. Also increased levels of
myeloperoxidase have been found in RA sera and
synovial fluid [27, 28]. We suppose that in seropositive
RA synovium neutrophils respond to the massive in-
flammatory reaction or presence of histiocytes in and
around the necrotic area. Myeloperoxidase staining
could be found in the middle of the necrotic area and
also in the intact tissue adjacent to the necrotic area. In
the necrotic tissue, these distinct defense mechanisms





Fig. 8 Histology of necrotic RA synovial tissue consisting of fibrinoid necrosis and sporadic intact cells. a H&E, (b) citrulline and homocitrulline
(F95), (c) PAD2, (d) and PAD3, (e) PAD4 and (f) MPO staining. The scale bar indicates 50 μm. Arrowhead intact cells, purple double-headed arrow
fibrinoid necrosis
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suggests, that myeloperoxidase from neutrophil granules
is present at active sites of inflammation in seropositive
RA synovial tissues and it could be from extracellular
traps or secreted. Detection of NETosis in tissue speci-
mens is a challenge. However, these events can create a
situation where citrulline and homocitrulline are present
simultaneously in large amount in host proteins that are
further presented to the inflammatory cells. This could
be a part of the process for RA autoantibody induction,
and at least partly explain the wide variety of antibody
specificities that can be found in RA sera. Overall, our
data supports the idea of repeated auto-vaccination as a
propagator of RA [29].
In relation to RA, myeloperoxidase could also have an
independent role in autoantibody development. The levels
of thiocyanate are elevated in blood of smokers [30] and
myeloperoxidase facilitates homocitrulline formation
through a chemical reaction originating from thiocyanate
[31]. Antibodies binding to carbamylated proteins have
been found in RA sera and these were also suggested to
be related to joint damage [9]. Here we found high levels
of antibodies binding to citrulline- and homocitrulline-
containing collagen telopeptides. As shown before [10],
the presence of these antibodies was overlapping with
ACPA positivity, but was not in clear relation with tissue
citrulline and homocitrulline levels. Here it should be
noted that not all of the sera analyzed were taken at the
time of the operation and thus the antibody titers may not
directly reflect the situation at the time of the operation.
In general, the levels of these antibodies were highest in
the seropositive RA knee and MTP subgroups that
showed also the highest local tissue levels of citrulline and
homocitrulline. Thus, the presence of high levels of citrul-
line- and homocitrulline-containing proteins in ACPA
and carbamylated antibody-positive individuals could lead
to persistence of inflammation leading to progression of
tissue damage. The chemical protein modifications are
still not enough for antibody induction as shown recently
[32], but probably also genetic predisposition is needed.
In clinical perspective, our data suggests that there are
distinct processes in RA and OA synovial tissue that
have differences even between anatomical locations. In
the necrotic tissue, the altered self-proteins are pre-





Fig. 9 Histology of rheumatoid nodule. a H&E, (b) citrulline and homocitrulline (F95), (c) PAD2, (d) PAD3, (e) PAD4 and (f) MPO staining. The
scale bar indicates 50 μm. Purple double-headed arrow fibrinoid necrosis, blue double-headed arrow palisading histiocytes, black double-headed
arrow stromal cells







Fig. 10 Cellular localization of (a) F95 in RA, (b) PAD2 in RA, (c) PAD3 in RA, (d) MPO in RA, (e) PAD4 in RA and (f) PAD4 staining in OA. The scale










Fig. 11 PAD3 (c, g) co-localization with citrulline- and homocitrulline-binding F95 antibody (b) and macrophage marker KP1 (CD68) (g) in the intact
tissue adjacent to necrosis in rheumatoid nodule. PAD3 HIER was performed in pH 9 Tris-EDTA. PAD3 and F95 bound abundantly to the cytoplasm of
cells adjacent to necrosis (d). PAD3 co-localized with KP1 in the cells adjacent to necrosis (h). Asterisk necrosis, double-headed arrow
palisading histiocytes
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response that could cause secondary inflammation in
other joints leading to chronic inflammation and tissue
erosions. The removal of the necrotic tissue is the only
way of extinguishing the local inflammatory process
that the necrotic tissue upholds. In RA, the local and
systemic control of inflammation is disturbed. These
findings however raise new questions on pathophysi-
ology behind the necrotizing events in RA synovium
and the clinical possibilities on how to prevent these
events. Moreover, since in RA the body is not able to
remove all necrotic tissue that upholds the inflamma-
tion, surgery might indeed still be needed, until the
mechanism behind the formation of necrotic lesions is
fully understood and curable by other means. For sur-
geons, this means that synovial biopsies should be
taken while performing synovectomy and if necrosis is
seen this suggests that the patient could benefit from
more extensive surgery. Removal of the necrotic mass
and activated synovial tissue could be a key element in
alleviating the local symptoms of the disease.
Some study limitation issues need to be taken into ac-
count while interpreting these results. The RA patient
tissues were collected from patients with a long-lasting
disease with severe tissue alterations in the joints and
there is a selection bias, since all patients had to
undergo surgery. The patients’ history of smoking and
the medication in use are confounding factors and the
tissue piece used for analyses only presents a small area
of the synovial tissue. In addition, the method used
here for citrulline and homocitrulline detection is semi-
quantitative and based on a chemical modification reac-
tion after hydrolysis of the tissue. Some citrulline or
homocitrulline might be lost during hydrolysis and the
chemical modification reaction is done individually to
each sample, which may somewhat affect the result, so
the absolute amounts of citrulline and homocitrulline
could be somewhat greater than reported here, if a
direct determination method was used. Despite these
shortcomings, significant differences between groups
could be detected and hence, the data is reliable albeit
limited due to currently usable methodology.
Conclusions
In conclusion, this study adds to the current knowledge
by showing neutrophil enzyme myeloperoxidase in
seropositive RA synovial tissue with homocitrulline.
Disperse staining patterns of myeloperoxidase suggests
NETosis or myeloperoxidase release from neutrophils.
NETosis involves also peptidyl arginine deiminases and
is a process creating citrullinated proteins released in
the extracellular space. These findings can further
explain the RA progression and disease mechanism.
Key messages
 Citrullination and homocitrullination are present
simultaneously in necrotic RA synovial tissue.
 Myeloperoxidase is found in seropositive RA
synovial tissue and not in seronegative RA or OA.
 Myeloperoxidase and necrosis are more frequent in
the metatarsal synovial tissues compared to knee
synovial tissues.
 These results suggest neutrophil involvement in
seropositive RA synovial inflammation.
Hoechst/PADI4/KP1Hoechst/PADI4/F95
Fig. 12 PAD4 co-localization with citrulline- and homocitrulline-binding F95 antibody and macrophage marker KP1 (CD68) in the intact tissue
adjacent necrosis in rheumatoid nodule. PAD4 HIER was performed in pH 6 citrate buffer. PAD4 and F95 bound abundantly to the nucleuses
and somewhat to the cytoplasm of cells surrounding the necrotic area. No nuclear staining was detected in the cells adjacent to necrosis.
PAD4 co-localized with KP1 in the cells surrounding necrosis. Asterisk necrosis, double-headed arrow palisading histiocytes
Turunen et al. Arthritis Research & Therapy  (2016) 18:239 Page 13 of 15
Abbreviations
ACPA: anti-citrullinated protein/peptide antibodies; CRP: C-reactive protein;
DMARDS: disease-modifying antirheumatic drugs; HPLC: high-performance
liquid chromatography; Ig: immunoglobulin; MTP: metatarsophalangeal;
NET: neutrophil extracellular trap; OA: osteoarthritis; PAD: peptidylarginine
deiminase; RA: rheumatoid arthritis; RF: rheumatoid factor; TNF-α: tumor
necrosis factor alpha
Acknowledgements
We thank Ms Katja Koukkula, Ms Tarja Huhta, Ms Riitta Vuento and BSc
Henna Salo for expert technical assistance and Sigrid Juselius Foundation
for participation in the funding of this study.
Funding
ST is funded by Sigrid Juselius Foundation; JH is funded by Oulu University
Hospital and The Finnish Medical Foundation; TN, MV and JM are funded by
Oulu University Hospital; JR and PL are funded by Oulu University Hospital
and University of Oulu.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
ST participated in study design, HPLC analyses, ELISA analyses,
immunohistochemistry, Western blotting and interpretation of the data,
and drafted the manuscript. JH, TN and MV participated in sample and
data collection and analysis. JM participated in histological analyses
and interpretation of the data. JR participated in the study design
and interpretation of the data. PL participated in study design, data
collection and drafting of the manuscript. All authors participated in
critical revision of the manuscript and read and approved the final
version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
There are no identifiable data presented in this study.
Ethical approval and consent to participate
The research plan was approved by the Ethics Committee of Oulu University
Hospital, the guidelines of the Declaration of Helsinki were followed and an
informed consent was signed by all patients.
Author details
1Department of Anatomy and Cell Biology, Cancer and Translational
Medicine Research Unit, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland.
2Division of Orthopedic Surgery, Oulu University Hospital, Oulu, Finland.
3Division of Rheumatology, Department of Internal Medicine, Oulu University
Hospital, Oulu, Finland. 4Department of Pathology, Cancer and Translational
Medicine Research Unit, University of Oulu and Oulu University Hospital, Oulu,
Finland. 5Department of Clinical Chemistry, Cancer and Translational Medicine
Research Unit, University of Oulu, Oulu, Finland. 6Northern Finland Laboratory
Centre NordLab, Oulu University Hospital, Oulu, Finland.
Received: 14 June 2016 Accepted: 27 September 2016
References
1. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der
Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP,
Dijkmans BA. Specific autoantibodies precede the symptoms of
rheumatoid arthritis: a study of serial measurements in blood donors.
Arthritis Rheum. 2004;50(2):380–6.
2. Chatzidionisyou A, Catrina AI. The lung in rheumatoid arthritis, cause or
consequence? Curr Opin Rheumatol. 2016;28(1):76–82.
3. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Mechin MC,
Vincent C, Nachat R, Yamada M, Takahara H, Simon M, Guerrin M, Serre G.
Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3,
and PAD-6 are expressed in rheumatoid arthritis synovium in close association
with tissue inflammation. Arthritis Rheum. 2007;56(11):3541–53.
4. U KP, Subramanian V, Nicholas AP, Thompson PR, Ferretti P. Modulation of calcium-
induced cell death in human neural stem cells by the novel peptidylarginine
deiminase-AIF pathway. Biochim Biophys Acta. 2014;1843(6):1162–71.
5. Vossenaar ER, van Venrooij WJ. Citrullinated proteins: sparks that may ignite
the fire in rheumatoid arthritis. Arthritis Res Ther. 2004;6(3):107–11.
6. Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil
extracellular traps may serve as self-antigens and mediate organ damage
in autoimmune diseases. Front Immunol. 2012;3:380.
7. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S,
Knight JS, Friday S, Li S, Patel RM, Subramanian V, Thompson P, Chen P, Fox DA,
Pennathur S, Kaplan MJ. NETs are a source of citrullinated autoantigens and
stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med.
2013;5(178):178ra40.
8. Shelef MA, Bennin DA, Mosher DF, Huttenlocher A. Citrullination of fibronectin
modulates synovial fibroblast behavior. Arthritis Res Ther. 2012;14(6):R240.
9. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA,
Levarht NE, van der Helm-van Mil AH, Cerami A, Huizinga TW, Toes RE,
Trouw LA. Autoantibodies recognizing carbamylated proteins are present
in sera of patients with rheumatoid arthritis and predict joint damage.
Proc Natl Acad Sci U S A. 2011;108(42):17372–7.
10. Turunen S, Hannonen P, Koivula MK, Risteli L, Risteli J. Separate and
overlapping specificities in rheumatoid arthritis antibodies binding to
citrulline- and homocitrulline-containing peptides related to type I and II
collagen telopeptides. Arthritis Res Ther. 2015;17(1):2.
11. Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Kallberg H,
Malmstrom V, Israelsson L, Hreggvidsdottir H, Verduijn W, Klareskog L,
Alfredsson L, Huizinga TW, Toes RE, Lundberg K, van der Woude D. Anti-
CarP antibodies in two large cohorts of patients with rheumatoid arthritis
and their relationship to genetic risk factors, cigarette smoking and other
autoantibodies. Ann Rheum Dis. 2014;73(10):1761–8.
12. Turunen S, Koivula MK, Risteli L, Risteli J. Ureido group-specific antibodies
are induced in rabbits immunized with citrulline- or homocitrulline-
containing antigens. Autoimmunity. 2016;1–7. [Epub ahead of print].
13. Turunen S, Koivula MK, Risteli L, Risteli J. Anticitrulline antibodies can be
caused by homocitrulline-containing proteins in rabbits. Arthritis Rheum.
2010;62(11):3345–52.
14. Scinocca M, Bell DA, Racape M, Joseph R, Shaw G, McCormick JK, Gladman
DD, Pope J, Barra L, Cairns E. Antihomocitrullinated fibrinogen antibodies
are specific to rheumatoid arthritis and frequently bind citrullinated
proteins/peptides. J Rheumatol. 2014;41(2):270–9.
15. Klebanoff SJ: Myeloperoxidase-halide-hydrogen peroxide antibacterial
system. J Bacteriol. 1968;95(6):2131–2138.
16. Klebanoff S, Clem W, Luebke R. The peroxidasethiocyanate-hydrogen
peroxide antimicrobial system. Biochimica et Biophysica Acta (BBA) -
General Subjects. 1966;117(1):63–72.
17. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO,
Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH,
Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW,
Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW,
Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP,
Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis
classification criteria: an American College of Rheumatology/European League
Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.
18. Turunen S, Koivula MK, Melkko J, Alasaarela E, Lehenkari P, Risteli J. Different
amounts of protein-bound citrulline and homocitrulline in foot joint
tissues of a patient with anti-citrullinated protein antibody positive
erosive rheumatoid arthritis. J Transl Med. 2013;11(1):224.
19. Turunen S, Koivula MK, Nicholas AP, Risteli L, Risteli J. Homocitrulline: An
analog and Confounder Related to Citrulline. In: Nicholas A, Bhattacharya S,
editors. Protein Deimination in Human Health and Disease. New York:
Springer Science + Business Media; 2014. p. 367–76.
20. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C,
de Rooij DJ, Barrera P, Zendman AJ, van Venrooij WJ. Expression and
activity of citrullinating peptidylarginine deiminase enzymes in
monocytes and macrophages. Ann Rheum Dis. 2004;63(4):373–81.
21. Olivares-Martinez E, Hernandez-Ramirez DF, Nunez-Alvarez CA, Cabral AR,
Llorente L. The amount of citrullinated proteins in synovial tissue is related
to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels. Clin
Rheumatol. 2016;35(1):55–61.
Turunen et al. Arthritis Research & Therapy  (2016) 18:239 Page 14 of 15
22. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, Ryu JH,
Baeten D, Matteson EL. Citrullination in extra-articular manifestations of
rheumatoid arthritis. Rheumatology (Oxford). 2007;46(1):70–5.
23. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS,
Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria.
Science. 2004;303(5663):1532–5.
24. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, Hayama R, Leonelli L, Han H,
Grigoryev SA, Allis CD, Coonrod SA. Histone hypercitrullination mediates
chromatin decondensation and neutrophil extracellular trap formation.
J Cell Biol. 2009;184(2):205–13.
25. Sur Chowdhury C, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. Enhanced
neutrophil extracellular trap generation in rheumatoid arthritis: analysis of
underlying signal transduction pathways and potential diagnostic utility.
Arthritis Res Ther. 2014;16(3):R122.
26. Spengler J, Lugonja B, Ytterberg AJ, Zubarev RA, Creese AJ, Pearson MJ,
Grant MM, Milward M, Lundberg K, Buckley CD, Filer A, Raza K, Cooper PR,
Chapple IL, Scheel-Toellner D. Release of active peptidyl arginine deiminases by
neutrophils can explain production of extracellular citrullinated autoantigens in
RA synovial fluid. Arthritis Rheumatol. 2015;67(12):3135–45.
27. Nzeusseu Toukap A, Delporte C, Noyon C, Franck T, Rousseau A, Serteyn D,
Raes M, Vanhaeverbeek M, Moguilevsky N, Nève J, Vanhamme L, Durez P,
Van Antwerpen P, Zouaoui Boudjeltia K. Myeloperoxidase and its products
in synovial fluid of patients with treated or untreated rheumatoid arthritis.
Free Radical Research. 2014;48(4):461–465.
28. Levent Ediz. Relationship between Anti-CCP Antibodies and Oxidant and
Anti-Oxidant Activity in Patients with Rheumatoid Arthritis. International
Journal of Medical Sciences:139.
29. Tsumiyama K, Miyazaki Y, Shiozawa S. Self-organized criticality theory of
autoimmunity. PLoS One. 2009;4(12), e8382.
30. Zil-a-Rubab, Rahman MA. Serum thiocyanate levels in smokers, passive
smokers and never smokers. J Pak Med Assoc. 2006;56(7):323–6.
31. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF,
Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation links inflammation,
smoking, uremia and atherogenesis. Nat Med. 2007;13(10):1176–84.
32. Verheul MK, van Erp SJ, van der Woude D, Levarht EW, Mallat MJ, Verspaget HW,
Stolk J, Toes RE, van der Meulen-de Jong AE, Hiemstra PS, van Kooten C,
Trouw LA. Anti-carbamylated protein antibodies: a specific hallmark for
rheumatoid arthritis. Comparison to conditions known for enhanced
carbamylation; renal failure, smoking and chronic inflammation. Ann
Rheum Dis. 2016;75(8):1575–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Turunen et al. Arthritis Research & Therapy  (2016) 18:239 Page 15 of 15
